BRKR vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak fundamental profile with a Piotroski F-Score of just 2/9, indicating poor financial health. Despite a reasonable Price/Book of 3.13 and a Forward P/E of 23.49 that is below sector average, the company is unprofitable with a negative profit margin (-0.61%) and ROE (-1.09%). Revenue is flat, earnings volatility is high, and insider selling of $2.76M over the past six months signals management skepticism. While the technical rebound from 6-month lows has lifted price performance (+20.3% over 6M), the long-term trend remains weak with a 3Y return of -28.5%, and analyst target of $54.07 appears optimistic given deteriorating fundamentals.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BRKR vs LLY: Head-to-Head Comparison
This page compares Bruker Corporation (BRKR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.